CureVac Historical Balance Sheet

CVAC Stock

USD 2.98 0.10 3.47%

Trend analysis of CureVac NV balance sheet accounts such as Other Current Liab of 74.8 M, Total Current Liabilities of 184.1 M or Total Stockholder Equity of 447.3 M provides information on CureVac NV's total assets, liabilities, and equity, which is the actual value of CureVac NV to its prevalent stockholders. By breaking down trends over time using CureVac NV balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining CureVac NV latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CureVac NV is a good buy for the upcoming year.

CureVac NV Inventory

23.59 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.

About CureVac Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of CureVac NV at a specified time, usually calculated after every quarter, six months, or one year. CureVac NV Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of CureVac NV and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which CureVac currently owns. An asset can also be divided into two categories, current and non-current.

CureVac NV Balance Sheet Chart

CureVac NV Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how CureVac NV uses and utilizes its capital. It also shows what exactly a company owns and owes.

At present, CureVac NV's Other Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Current Deferred Revenue is expected to grow to about 56.5 M, whereas Other Current Liabilities is forecasted to decline to about 74.8 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab Property Plant Equipment

Add Fundamental

Total Assets

Total assets refers to the total amount of CureVac NV assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in CureVac NV books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on CureVac NV balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of CureVac NV are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from CureVac NV's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into CureVac NV current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.At present, CureVac NV's Other Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Current Deferred Revenue is expected to grow to about 56.5 M, whereas Other Current Liabilities is forecasted to decline to about 74.8 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	176.3M	46.2M	90.5M	74.8M
Total Assets	1.2B	860.5M	788.9M	838.8M

Other Current Liab Total Assets

CureVac NV balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab
Total Assets		0.8	0.94	0.98	0.75	0.97	0.72	0.92	-0.97	-0.67	0.69	0.98	0.72	-0.25	-0.34	0.98	0.41	0.91	-0.1	-0.8	0.76	0.77	0.91	0.39	0.96	-0.32
Other Current Liab	0.8		0.96	0.85	0.3	0.86	0.75	0.57	-0.72	-0.69	0.92	0.74	0.74	-0.31	-0.4	0.73	0.46	0.8	0.26	-0.69	0.29	0.97	0.86	0.24	0.69	-0.49
Total Current Liabilities	0.94	0.96		0.96	0.52	0.95	0.77	0.76	-0.88	-0.71	0.87	0.89	0.76	-0.27	-0.38	0.89	0.45	0.89	0.09	-0.77	0.53	0.93	0.93	0.29	0.85	-0.43
Total Stockholder Equity	0.98	0.85	0.96		0.62	1.0	0.82	0.84	-0.92	-0.77	0.78	0.93	0.82	-0.31	-0.45	0.93	0.53	0.95	0.05	-0.79	0.63	0.83	0.86	0.38	0.9	-0.47
Other Liab	0.75	0.3	0.52	0.62		0.61	0.18	0.95	-0.84	-0.2	0.06	0.84	0.19	-0.09	0.03	0.85	-0.13	0.53	-0.56	-0.49	0.96	0.18	0.71	0.49	0.87	0.21
Net Tangible Assets	0.97	0.86	0.95	1.0	0.61		0.84	0.83	-0.91	-0.77	0.77	0.92	0.84	-0.34	-0.47	0.91	0.54	0.95	0.08	-0.79	0.61	0.83	0.85	0.4	0.88	-0.48
Property Plant And Equipment Net	0.72	0.75	0.77	0.82	0.18	0.84		0.45	-0.55	-0.96	0.79	0.59	1.0	-0.55	-0.78	0.57	0.9	0.9	0.58	-0.8	0.21	0.8	0.49	0.4	0.54	-0.8
Current Deferred Revenue	0.92	0.57	0.76	0.84	0.95	0.83	0.45		-0.96	-0.42	0.36	0.97	0.45	-0.16	-0.12	0.97	0.11	0.74	-0.39	-0.67	0.93	0.48	0.86	0.47	0.98	0.0
Net Debt	-0.97	-0.72	-0.88	-0.92	-0.84	-0.91	-0.55	-0.96		0.48	-0.56	-0.99	-0.55	0.07	0.12	-0.99	-0.19	-0.78	0.33	0.68	-0.85	-0.65	-0.93	-0.3	-0.98	0.1
Retained Earnings	-0.67	-0.69	-0.71	-0.77	-0.2	-0.77	-0.96	-0.42	0.48		-0.72	-0.54	-0.96	0.72	0.9	-0.53	-0.87	-0.92	-0.64	0.79	-0.18	-0.74	-0.44	-0.57	-0.51	0.86
Accounts Payable	0.69	0.92	0.87	0.78	0.06	0.77	0.79	0.36	-0.56	-0.72		0.58	0.78	-0.19	-0.45	0.57	0.62	0.75	0.37	-0.63	0.1	0.98	0.66	0.0	0.52	-0.65
Cash	0.98	0.74	0.89	0.93	0.84	0.92	0.59	0.97	-0.99	-0.54	0.58		0.59	-0.15	-0.2	1.0	0.25	0.83	-0.26	-0.74	0.85	0.68	0.93	0.37	0.99	-0.16
Non Current Assets Total	0.72	0.74	0.76	0.82	0.19	0.84	1.0	0.45	-0.55	-0.96	0.78	0.59		-0.55	-0.78	0.57	0.9	0.91	0.57	-0.79	0.22	0.79	0.48	0.4	0.54	-0.8
Non Currrent Assets Other	-0.25	-0.31	-0.27	-0.31	-0.09	-0.34	-0.55	-0.16	0.07	0.72	-0.19	-0.15	-0.55		0.89	-0.14	-0.5	-0.56	-0.68	0.39	0.07	-0.26	-0.13	-0.89	-0.14	0.68
Other Assets	-0.34	-0.4	-0.38	-0.45	0.03	-0.47	-0.78	-0.12	0.12	0.9	-0.45	-0.2	-0.78	0.89		-0.19	-0.81	-0.7	-0.8	0.53	0.11	-0.45	-0.1	-0.67	-0.17	0.91
Cash And Short Term Investments	0.98	0.73	0.89	0.93	0.85	0.91	0.57	0.97	-0.99	-0.53	0.57	1.0	0.57	-0.14	-0.19		0.22	0.82	-0.28	-0.72	0.85	0.66	0.93	0.37	0.99	-0.15
Net Receivables	0.41	0.46	0.45	0.53	-0.13	0.54	0.9	0.11	-0.19	-0.87	0.62	0.25	0.9	-0.5	-0.81	0.22		0.68	0.75	-0.69	-0.05	0.58	0.1	0.26	0.22	-0.82
Common Stock Total Equity	0.91	0.8	0.89	0.95	0.53	0.95	0.9	0.74	-0.78	-0.92	0.75	0.83	0.91	-0.56	-0.7	0.82	0.68		0.29	-0.85	0.51	0.8	0.73	0.56	0.8	-0.66
Common Stock Shares Outstanding	-0.1	0.26	0.09	0.05	-0.56	0.08	0.58	-0.39	0.33	-0.64	0.37	-0.26	0.57	-0.68	-0.8	-0.28	0.75	0.29		-0.27	-0.59	0.34	-0.23	0.3	-0.29	-0.79
Short Term Investments	-0.8	-0.69	-0.77	-0.79	-0.49	-0.79	-0.8	-0.67	0.68	0.79	-0.63	-0.74	-0.79	0.39	0.53	-0.72	-0.69	-0.85	-0.27		-0.56	-0.72	-0.64	-0.44	-0.77	0.4
Non Current Liabilities Total	0.76	0.29	0.53	0.63	0.96	0.61	0.21	0.93	-0.85	-0.18	0.1	0.85	0.22	0.07	0.11	0.85	-0.05	0.51	-0.59	-0.56		0.21	0.68	0.32	0.89	0.27
Inventory	0.77	0.97	0.93	0.83	0.18	0.83	0.8	0.48	-0.65	-0.74	0.98	0.68	0.79	-0.26	-0.45	0.66	0.58	0.8	0.34	-0.72	0.21		0.77	0.12	0.63	-0.58
Other Current Assets	0.91	0.86	0.93	0.86	0.71	0.85	0.49	0.86	-0.93	-0.44	0.66	0.93	0.48	-0.13	-0.1	0.93	0.1	0.73	-0.23	-0.64	0.68	0.77		0.29	0.91	-0.1
Other Stockholder Equity	0.39	0.24	0.29	0.38	0.49	0.4	0.4	0.47	-0.3	-0.57	0.0	0.37	0.4	-0.89	-0.67	0.37	0.26	0.56	0.3	-0.44	0.32	0.12	0.29		0.39	-0.36
Total Liab	0.96	0.69	0.85	0.9	0.87	0.88	0.54	0.98	-0.98	-0.51	0.52	0.99	0.54	-0.14	-0.17	0.99	0.22	0.8	-0.29	-0.77	0.89	0.63	0.91	0.39		-0.09
Deferred Long Term Liab	-0.32	-0.49	-0.43	-0.47	0.21	-0.48	-0.8	0.0	0.1	0.86	-0.65	-0.16	-0.8	0.68	0.91	-0.15	-0.82	-0.66	-0.79	0.4	0.27	-0.58	-0.1	-0.36	-0.09

Click cells to compare fundamentals

CureVac NV Account Relationship Matchups

CureVac NV balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	130.6M	1.5B	1.2B	860.5M	788.9M	838.8M
Other Current Liab	13.3M	68.8M	176.3M	46.2M	90.5M	74.8M
Total Current Liabilities	28.1M	247.6M	357.7M	156.2M	186.5M	184.1M
Total Stockholder Equity	(42.8M)	711.3M	688.5M	533.3M	517.4M	447.3M
Net Tangible Assets	(48.2M)	697.9M	676.2M	501.5M	576.7M	407.8M
Property Plant And Equipment Net	66.8M	104.8M	200.4M	241.7M	278.9M	172.0M
Current Deferred Revenue	7.5M	158.0M	55.8M	36.8M	44.6M	56.5M
Net Debt	48.5M	(1.3B)	(782.6M)	(453.7M)	(360.9M)	(379.0M)
Retained Earnings	(515.9M)	(645.1M)	(1.1B)	(1.3B)	(1.6B)	(1.5B)
Accounts Payable	5.3M	17.6M	122.3M	68.2M	46.4M	49.3M
Cash	30.7M	1.3B	811.5M	495.8M	402.8M	565.5M
Non Current Assets Total	73.4M	121.5M	218.2M	276.4M	310.1M	192.9M
Non Currrent Assets Other	967K	1.1M	1.2M	1.7M	(14.2M)	(13.5M)
Other Assets	6.3M	7.5M	5.6M	3.0M	1.0	0.95
Cash And Short Term Investments	32.1M	1.3B	816.1M	500.3M	402.8M	575.1M
Net Receivables	17.7M	1.8M	18.5M	39.4M	35.9M	22.0M
Common Stock Shares Outstanding	186.9M	132.2M	186.0M	189.1M	220.8M	200.0M
Short Term Investments	1.5M	2.6M	4.6M	4.5M	2.7M	2.5M
Liabilities And Stockholders Equity	130.6M	1.5B	1.2B	860.5M	788.9M	838.8M
Non Current Liabilities Total	145.3M	552.4M	112.0M	171.0M	85.0M	150.8M
Capital Lease Obligations	14.1M	55.3M	28.9M	42.1M	41.8M	33.4M
Inventory	6.2M	14.5M	56.2M	24.0M	24.8M	23.6M
Other Current Assets	1.2M	48.3M	49.2M	5.3M	15.2M	22.3M
Other Stockholder Equity	493.4M	1.4B	(5.8M)	(1.5M)	2.1B	2.2B
Total Liab	173.4M	800.0M	469.8M	327.2M	271.5M	391.5M
Deferred Long Term Liab	966K	1.0M	515K	302K	271.8K	258.2K
Net Invested Capital	22.2M	711.3M	688.5M	533.3M	516.9M	459.1M
Property Plant And Equipment Gross	61.7M	104.8M	247.4M	258.7M	301.8M	186.0M
Total Current Assets	57.2M	1.4B	940.0M	584.0M	478.8M	645.9M
Accumulated Other Comprehensive Income	472.4M	1.3B	1.7B	1.8B	(67.1K)	(63.7K)
Non Current Liabilities Other	529K	284K	264K	19K	17.1K	16.2K
Net Working Capital	29.1M	1.1B	582.3M	427.8M	292.0M	461.7M
Short Term Debt	2.0M	3.2M	3.5M	5.0M	5.0M	3.5M
Intangible Assets	5.7M	14.1M	13.2M	19.3M	15.9M	13.7M

Pair Trading with CureVac NV

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CureVac NV position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CureVac NV will appreciate offsetting losses from the drop in the long position's value.

Moving together with CureVac Stock

0.79

VRAX

Virax Biolabs Group Fiscal Year End 12th of June 2024

Pair Corr

Moving against CureVac Stock

0.87	ACRV	Acrivon Therapeutics Financial Report 14th of May 2024	Pair Corr
0.7	RVMD	Revolution Medicines Financial Report 13th of May 2024	Pair Corr
0.62	INDP	Indaptus Therapeutics	Pair Corr
0.53	FBRX	Forte Biosciences Financial Report 20th of May 2024	Pair Corr
0.42	PULM	Pulmatrix	Pair Corr

The ability to find closely correlated positions to CureVac NV could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CureVac NV when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CureVac NV - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CureVac NV to buy it.

The correlation of CureVac NV is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CureVac NV moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CureVac NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for CureVac NV can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:

How To Invest In CureVac

Details

Is CureVac Stock a good investment?

Details

What is CureVac NV's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.

Note that the CureVac NV information on this page should be used as a complementary analysis to other CureVac NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for CureVac Stock analysis

When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.

	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Commodity Directory Find actively traded commodities issued by global exchanges
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency

Is CureVac NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.27)

Revenue Per Share

0.243

Quarterly Revenue Growth

0.931

Return On Assets

(0.21)

Return On Equity

(0.50)

The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CureVac Historical Balance Sheet

CureVac NV Inventory

23.59 Million

About CureVac Balance Sheet Analysis

CureVac NV Balance Sheet Chart

Total Assets

Total Current Liabilities

CureVac NV balance sheet Correlations

CureVac NV Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CureVac NV balance sheet Accounts

Pair Trading with CureVac NV

Moving together with CureVac Stock

Moving against CureVac Stock

Complementary Tools for CureVac Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Cash
Total Liab	+ 0.99	Cash And Short Term Investments
Total Stockholder Equity	+ 0.98	Total Assets

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Liab	- 0.98	Net Debt
Net Debt	- 0.97	Total Assets
Non Current Assets Total	- 0.96	Retained Earnings
Net Debt	- 0.96	Current Deferred Revenue